A tribute to Dr Ahmed Elsharkawy

March 9, 2026

We are deeply saddened by the passing of Dr Ahmed Elsharkawy, a dedicated trustee of the British Liver Trust and a passionate advocate for people affected by liver disease.

Ahmed brought extraordinary commitment, insight and compassion to everything he did. As a consultant hepatologist, he worked tirelessly to improve the lives of patients through earlier diagnosis and better treatments.

As a trustee of the British Liver Trust and Children’s Liver Disease Foundation, Ahmed was a thoughtful and principled member of our Board. He was generous with his time, supportive of colleagues and unwavering in his focus on what mattered most – better care, greater awareness and better futures for patients and families affected by liver disease.

Those who knew and worked with Ahmed will remember not only his expertise and integrity, but also his warmth, humour and kindness.

Ahmed leaves a lasting legacy in the progress made towards improved management and care for liver disease, with a particular passion for improving diagnosis and outcomes for people with viral hepatitis.

He will be greatly missed by everyone at the British Liver Trust and across the liver community.

Our thoughts are with his family, friends and colleagues at this very sad time.

More news

A new chapter for liver health: together we are Liver UK

A new chapter for liver health: together we are Liver UK

Today, we take the next step in that journey as Liver UK: a stronger, clearer and more united voice for liver health.
Potential for hundreds more liver transplants after NICE recommends new life-saving liver procedure for NHS use

Potential for hundreds more liver transplants after NICE recommends new life-saving liver procedure for NHS use

The British Liver Trust welcomes the news that hundreds more liver transplants could be carried out after a new procedure that supplies a donor liver with oxygen before removal was approved by NICE for use in the NHS.   In-situ ...
New hope for people living with MASH as two treatments receive MHRA approval

New hope for people living with MASH as two treatments receive MHRA approval

People living with metabolic dysfunction-associated steatohepatitis (MASH) have received encouraging news, with the UK medicines regulator approving two treatments for the condition within the past month. The Medicines and Healthcare ...
No results found.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.